Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results [Yahoo! Finance]
Annovis Bio, Inc. (ANVS)
Company Research
Source: Yahoo! Finance
developing novel therapies for neurodegenerative diseases, provided updates from across the organization and announced first quarter financial results. Clinical Updates AD Phase II/III Study On April 29, Annovis announced statistically significant Phase II/III data in patients with early Alzheimer's disease (AD). Significantly higher rate of improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD; Improvement in cognition measured by ADAS-Cog 11 at three months was 3.3 points as compared to 0.3 for placebo, consistent with previous Phase II AD/PD and Discovery studies; Plasma Tau protein levels were reduced, consistent with previous Phase II biomarker data. Based on the findings of this short study, Annovis plans to conduct a pivotal 18-month disease-modifying Phase III trial in biomarker-positive early AD patients. PD Phase III Study On January 24, Annovis refined the timeline for Parkinson's disease (PD) Phase III data
Show less
Read more
Impact Snapshot
Event Time:
ANVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANVS alerts
High impacting Annovis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
ANVS
News
- Annovis Bio Files Patent for New Composition of Matter for Buntanetap [Yahoo! Finance]Yahoo! Finance
- Annovis Bio Files Patent for New Composition of Matter for BuntanetapGlobeNewswire
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson's Disease Data [Yahoo! Finance]Yahoo! Finance
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease DataGlobeNewswire
- Annovis Bio Highlights New Alzheimer's Data at the Alzheimer's Association International Conference® 2024 [Yahoo! Finance]Yahoo! Finance
ANVS
Earnings
- 5/10/24 - Beat
ANVS
Sec Filings
- 6/21/24 - Form S-8
- 6/13/24 - Form 8-K
- 6/11/24 - Form 8-K
- ANVS's page on the SEC website